<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03001609</url>
  </required_header>
  <id_info>
    <org_study_id>AC201606AVTN06</org_study_id>
    <nct_id>NCT03001609</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC</brief_title>
  <official_title>An Open-Label, Non-Randomized, Single-Center Study to Determine the Absorption, Metabolism and Excretion of A Single Dose [14C] AC0010 in Patients With Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou ACEA Pharmaceutical Research Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hangzhou ACEA Pharmaceutical Research Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate Pharmacokinetics parameters of a single dose
      [14C] AC0010 in male Patients With Advanced NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the Absorption, Metabolism, Excretion and
      Pharmacokinetics of a single dose [14C] AC0010 in male Patients With Advanced NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics, Cumalative excretion and Metabolite of 14C-labeled AC0010</measure>
    <time_frame>up to 8 Days</time_frame>
    <description>Pharmacokinetics of 14C-labeled AC0010 Radioactivity in whole blood and plasma,Cumulative excretion of 14C-labeled AC0010 radioactivity in feces and urine,Metabolite identification of 14C-labeled AC0010 in plasma, urine and feces</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative analysis of plasma concentrations of unlabeled AC0010</measure>
    <time_frame>up to 8 Days</time_frame>
    <description>Quantitative analysis of plasma concentrations of unlabeled AC0010 using a validated LC-MS/MS method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AE) experienced by patients</measure>
    <time_frame>up to 8 Days</time_frame>
    <description>Number of adverse events (AE) experienced by patients to assess safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>AC0010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each participant will be given a single dose of 14C-labeled AC0010</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC0010</intervention_name>
    <description>Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi[14C]</description>
    <arm_group_label>AC0010</arm_group_label>
    <other_name>14C-labeled AC0010 oral</other_name>
    <other_name>AC0010MA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed and dated informed consent

          -  histologically or cytologically confirmed diagnosis of local advanced or recurrent
             NSCLC

          -  failed to the treatment of EGFR-TKI and harbored T790M mutation

          -  male, Age 18~ 65, have a body mass index (BMI) &gt;19 kg/m2

          -  ECOG PS:0-1,Life expectancy of more than 3 months

          -  main organs function is normal, laboratory values as listed below: blood test without
             blood transfusion within 14 days

               1. Haemoglobin &gt;100 g/L

               2. Absolute neutrophil count ≥2.0x10^9/L or WBC ≥3.5 x10^9/L

               3. Platelet count ≥ 80x10^9/L

               4. Total bilirubin ≤1.5xULN

               5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times
                  upper limit of normal (ULN)

               6. BUN≤1.5xULN

               7. Serum creatinine ≤1.5xULN or creatinine clearance ratio ≥60 mL/min

          -  Any prior treatment (chemotherapy, radiotherapy or surgery) must be completed over 4
             weeks(target therapy over 2 weeks) from the screening; Patients must have recovered
             from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03)

          -  International normalized ratio (INR) ≤ 1.5

          -  Patients and their partners should be willing to use methods of contraception or total
             abstinence from start of dosing until 6 months after discontinuing of study treatment

        Exclusion Criteria:

          -  Prior treated with AC0010 or allergic to drug or its formulation ingredients

          -  Patients receiving other anti-tumor therapy

          -  Impairment of GI disease, renal disorders or liver disease that may significantly
             alter the absorption and metabolic of AC0010 (e.g., Unable to swallow, liver, kidney
             or gastrointestinal partial resection, chronic diarrhea and intestinal obstruction)

          -  HCVAb positive, active hepatitis B (excluding HBV carriers), Hepatitis virus markers
             positive and receiving anti-virus drugs

          -  Meningeal metastasis; brain metastasis with whole brain radiotherapy; prior received
             hormones or mannitol for the brain metastasis

          -  Previous EGFR-TKI treatment related Interstitial lung disease history

          -  Known human immunodeficiency virus infection (HIV), other acquired or congenital
             immunodeficiency disease, or a history of organ transplantation

          -  Any severe and / or uncontrolled active infections

          -  Patients receiving concomitant immunosuppressive agents or high-dose corticosteroids

          -  Any severe and / or uncontrolled medical conditions

          -  Patients being treated with drugs recognized as being inhibitors or inducers of the
             liver isoenzyme in the last 4 weeks prior to registration in the current study

          -  Within 3 days prior to the treatment intaking of pitaya, pomelo, grapefruit, orange,
             mango and other fruit may affect drug metabolizing enzymes or juice

          -  Within 2 days prior to the treatment intaking of coffee, tea, cola, chocolate, or
             other caffeine containing beverages, alcoholic beverages and / or other alcoholic
             products

          -  Major surgery, incisional biopsy or traumatic injuries;

          -  Within 4 weeks prior to the screening patients with bleeding ≥ grade 3, non-healing
             wound, sever ulcer or bone fracture

          -  Patients received high dose irradiation treatment or other 14C-labeled drug within 1
             year

          -  Known a history of alcoholism or drug abuse

          -  Nicotine or urine drug testing was positive

          -  Participate in any clinical trial within 4 weeks prior to the screening

          -  Investigator judgment that patient is unsuitable to participate in study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Shao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongqian Shu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lihua Bao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2016</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

